Clinical Trial Update: Asia PDL1 Study Among NSCLC Patients

View source ↗

Summary

AstraZeneca reports that an Asia-Pacific PD-L1 study in locally advanced or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic NSCLC | Status: COMPLETED